PIGN-CDG families are funding yeast-powered drug repurposing screens and a fibroblast biobank for hit validation. We just completed a pilot repurposing screen, and an expanded screen is in progress.
Thanks for the article. It is good to see updates of all the hard work you are doing. I appreciate your science and patience.
I have a clarifying question, I hope that you will see this and answer it for me.
My question is about your pivot to the temperature-sensitive (ts) yeast mutants. I am a little confused by your description here. Did you engineer-in the 10 PIGN variants described above into the ts yeast, and then run those Pharmakon screens? Or is your data comparing ts yeast to non-ts yeast? Or is it something else that I am missing?
Thanks for the help and reply. I am looking forward to hearing more about this work.